Er du ikke helsepersonell? Besøk våre hjemmesider

Er du ikke helsepersonell?

Besøk gjerne våre sider for publikum.

Denne siden kan inneholde salgsfremmende materiell.

Handlekurv

User logged in

Rapporter bivirkning

Overlay Text

Kun for helsepersonell

Kan inneholde produktreklame

Din registrering er satt på vent

Din konto er aktivert, men fordi vårt system ikke umiddlebart kunne gjenkjenne deg som helsepersonell må det gjøres en manuell sjekk. Du vil motta en e-post med resulatet i løpet av få dager.

Fullført registrering – vent på godkjenning

Din konto er opprettet, men vi må likevel sjekke at du er registrert helsepersonell. Vi vil sende deg en e-post med resulatat i løpet av [5] dager.

I mellomtiden har du tilgang til alle tjenester på portalen.

Din registrering er satt på vent

Din konto er aktivert, men fordi vårt system ikke umiddlebart kunne gjenkjenne deg som helsepersonell må det gjøres en manuell sjekk. Du vil motta en e-post med resulatet i løpet av få dager.

Account activated – pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy access to all the latest news, events and resources on our website

X »

Anoro Ellipta 20 mcg

har blitt lagt til din handelkurv.

Se bestilling

Popup

Unit for Hours:H

Unit for Minutes: M

Filter redirection page URL: events-3-3.html

Filter Tags:Medical indications|Products|Therapy Area

Filter Tags values when filtered by all Tags:All Medical indications|All Products|All Therapy Area

OutofBox filter category name:Format

Filter Reset all button text:Reset All

Filter Apply button text:Apply

Events registration success message: Registration successfull

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successfull

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Tag Requirements value: all

Show More Naivagation Values: 10|25|50

Previous Text label: Previous

Next Text label: Next

Show Text label: Show:

Seats left Text: spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:$ciamTextareaNoCopyEmail

Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Pick section

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Severe Eosinophilic Asthma (SEA)

Nucala in 4 eosinophilic diseases

Nucala is the anti-IL-5 therapy that is approved for the treatment of 4 eosinophilic diseases.¹

Since March 2016 Nucala has been approved as an add-on treatment for SEA (severe eosinophilic asthma) in adults, adolescents and children aged 6 years and older. At the end of 2021 (November 2021) Nucala has also been approved for 3 other eosinophilic diseases in Norway: CRSwNP (chronic rhinosinusitis with nasal polyps), EGPA (eosinophilic granulomatosis with polyangiitis) and HES (hypereosinophilic syndrome).¹

For relevant scientific information on each indication, click on the button.

Severe Eosinophilic Asthma (SEA)

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

Eosinophilic Granulomatosis with polyangiitis (EGPA)

Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Hypereosinophilic Syndrome (HES)

Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

References

Nucala preparatomtale

Nucala is a trademark of the GSK group of companies

PM-NO-MPL-WCNT-230001 June 2023

Registrer deg!

Få siste nytt om våre produkter og terapiområder, delta på webinarer, bestill servicemateriell til deg og dine pasienter.

Registrer deg nå

GSK Norge hjemmeside

Sorry, this site is not supported on Android v4.3 and below.

Please update your operating system or use a different device.